

# V-Go<sup>®</sup> Dosing Guidance



## V-Go Options

V-Go Option	Preset Basal Insulin Rate Over 24 Hours	Available Bolus Insulin	Total Available Insulin
V-Go 20	20 U (0.83 U/hr)	36 U	56 U
V-Go 30	30 U (1.25 U/hr)	36 U	66 U
V-Go 40	40 U (1.67 U/hr)	36 U	76 U

## Initiating V-Go in Patients Switching from Multiple Daily Injections (MDI)

Patient's Weight	< 91 kg	91 - 113 kg	> 113 kg
	Initiate V-Go 20	Initiate V-Go 30	Initiate V-Go 40
	Start bolus dosing 3 clicks*/meal	Start bolus dosing 4 clicks*/meal	Start bolus dosing 5 clicks*/meal
	Consider 1 click* with snack		

\*1 click = 2 Units of insulin. The Bolus Delivery Button 18 times in every 24-hour period, for up to 36 U/day.

### Additional considerations for V-Go initiation dose:

- Total daily dose of insulin patients are actually taking versus what is being prescribed
- Adherence to current insulin regimen
- Blood glucose levels

## Titration Guidance

### 1 Optimise bolus dosing

- If mealtime glucose remains elevated, add an additional click (2 U)

### 2 Titrate basal

- If bolus dosing is optimised and HbA1c or fasting glucose remains elevated, adjust V-Go basal dose

**Recommend to evaluate insulin dosing within 2-5 days of initiating V-Go and ensure patients have a plan to manage hypoglycaemia and hyperglycaemia.**

## Patient Details

Full Name:

Date of Birth:

Weight:

Patient's Insulin Requirements (Total Daily Insulin Dose):

Insulin Prescribed:  Humalog<sup>®</sup>  NovoRapid<sup>®</sup>

Patients require a prescription for Humalog 10 mL Vials (PBS code: 8084L) or NovoRapid 10 mL Vials (PBS code: 8571D)

V-Go Option Chosen:  V-Go 20  V-Go 30  V-Go 40

## Prescribing Doctor's Details

Doctor Name:

Date:

**Please note:** the dosage guidance provided above should only be used as a guide and is not a substitute for clinical judgment and the individual needs of the patient. AMSL Diabetes will not be liable for any decisions made or actions taken by healthcare professionals in reliance on this information. We would encourage all healthcare professionals to review current standards of care regarding insulin dosing guidance from national diabetes associations for dosage consideration.

For more information on V-Go, please contact the AMSL Diabetes Customer Care Team on **1300 851 056** or at [diabetes@amsl.com.au](mailto:diabetes@amsl.com.au)

[amsl diabetes.com.au](http://amsl diabetes.com.au)    

Important risk information: if regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycaemia. The following conditions may occur during insulin therapy with V-Go: hypoglycaemia (low blood glucose) or hyperglycaemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing. ARTG 304161. PR-100-278 January 2019

